MX2022007486A - Variantes de progranulina. - Google Patents

Variantes de progranulina.

Info

Publication number
MX2022007486A
MX2022007486A MX2022007486A MX2022007486A MX2022007486A MX 2022007486 A MX2022007486 A MX 2022007486A MX 2022007486 A MX2022007486 A MX 2022007486A MX 2022007486 A MX2022007486 A MX 2022007486A MX 2022007486 A MX2022007486 A MX 2022007486A
Authority
MX
Mexico
Prior art keywords
progranulin
variants
proteins
ftd
polypeptide
Prior art date
Application number
MX2022007486A
Other languages
English (en)
Inventor
Gunasekaran Kannan
Katrina W Lexa
Ankita Srivastava
Rachel Prorok
Gerald Maxwell Cherf
Ray L Y Low
Original Assignee
Denali Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Denali Therapeutics Inc filed Critical Denali Therapeutics Inc
Priority claimed from PCT/US2020/066831 external-priority patent/WO2021133907A1/en
Publication of MX2022007486A publication Critical patent/MX2022007486A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Abstract

Se proporcionan en la presente variantes de progranulina y proteínas de fusión que comprenden una variante de progranulina y un polipéptido Fc. También se proporcionan en la presente métodos para el uso de dichas proteínas para el tratamiento de trastornos asociados con la progranulina (por ejemplo, una enfermedad neurodegenerativa, tal como demencia frontotemporal (FTD)).
MX2022007486A 2019-12-23 2020-12-23 Variantes de progranulina. MX2022007486A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962953099P 2019-12-23 2019-12-23
US202063091819P 2020-10-14 2020-10-14
PCT/US2020/066831 WO2021133907A1 (en) 2019-12-23 2020-12-23 Progranulin variants

Publications (1)

Publication Number Publication Date
MX2022007486A true MX2022007486A (es) 2022-06-29

Family

ID=76437806

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022007486A MX2022007486A (es) 2019-12-23 2020-12-23 Variantes de progranulina.

Country Status (12)

Country Link
US (4) US20210188925A1 (es)
EP (1) EP4081536A1 (es)
JP (1) JP2023507846A (es)
KR (1) KR20220130678A (es)
CN (1) CN114981297A (es)
AU (1) AU2020411480B2 (es)
BR (1) BR112022012230A2 (es)
CA (1) CA3165846A1 (es)
CO (1) CO2022008648A2 (es)
IL (1) IL293994A (es)
MX (1) MX2022007486A (es)
PE (1) PE20230036A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018221731C1 (en) 2017-02-17 2021-11-18 Denali Therapeutics Inc. Engineered transferrin receptor binding polypeptides
MX2020002918A (es) 2017-10-02 2020-07-22 Denali Therapeutics Inc Proteinas de fusion que comprenden enzimas de terapia de reemplazo de enzimas.
CN114981297A (zh) 2019-12-23 2022-08-30 戴纳立制药公司 颗粒蛋白前体变体
IL302029A (en) 2020-10-14 2023-06-01 Denali Therapeutics Inc Fusion proteins containing sulfoglucosamine sulfohydrolase enzymes and methods thereof
CN116121306A (zh) * 2023-03-27 2023-05-16 迦进生物医药(上海)有限公司 一种human TfR1高表达的稳转细胞株及其构建方法和应用

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040110938A1 (en) 2000-02-24 2004-06-10 Parekh Rajesh Bhikhu Proteins, genes and their use for diagnosis and treatment of schizophrenia
WO2002044329A2 (en) 2000-11-30 2002-06-06 Uab Research Foundation Receptor-mediated uptake of peptides that bind the human transferrin receptor
NZ532027A (en) 2001-10-10 2008-09-26 Neose Technologies Inc Remodeling and glycoconjugation of peptides
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US20050123962A1 (en) 2003-10-28 2005-06-09 Agy Therapeutics, Inc. Regulated nucleic acids in pathogenesis of alzheimer's disease
WO2005077981A2 (en) 2003-12-22 2005-08-25 Xencor, Inc. Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES
ATE425186T1 (de) 2005-01-05 2009-03-15 F Star Biotech Forsch & Entw Synthetische immunoglobulindomänen mit in regionen des moleküls, die sich von den die komplementarität bestimmenden bereichen unterscheiden, modifizierten bindeeigenschaften
DK2037948T3 (en) 2006-05-30 2016-08-01 Mayo Foundation Detection and treatment of dementia
WO2008019187A2 (en) 2006-05-30 2008-02-14 Mayo Foundation For Medical Education And Research Detecting and treating dementia
PT2029742T (pt) 2006-06-07 2016-09-09 Genzyme Corp Terapia genética para esclerose lateral amiotrófica e outros transtornos da medula espinal
WO2008094687A2 (en) 2007-01-31 2008-08-07 New York University Gep, a novel chondrogenic growth factor and target in cartilage disorders
DE102007033359B4 (de) 2007-07-16 2010-12-02 Johann Wolfgang Goethe-Universität Frankfurt am Main Verwendung eines Granulins oder einer Granulin-ähnlichen Verbindung zur Therapie oder Prophylaxe von chronischen Schmerzen
WO2009089635A1 (en) 2008-01-16 2009-07-23 Neurodyn, Inc. Treating neurodegenerative diseases with progranulin (pgrn)
WO2010022175A1 (en) 2008-08-19 2010-02-25 Yale University Identification of sortilin as a neuronal receptor for the frontotemporal dementia protein, progranulin
EP2419121B1 (en) 2009-04-17 2018-07-18 New York University Peptides targeting tnf family receptors and antagonizing tnf action, compositions, methods and uses thereof
WO2012065248A1 (en) 2010-11-16 2012-05-24 Kay Denis G Method for increasing neprilysin expression and activity
SI2646470T1 (sl) 2010-11-30 2017-05-31 F. Hoffmann-La Roche Ag Protitelesa proti receptorjem antitransferina in njihova uporaba za prenos terapevtskega enoverižnega variabilnega fragmenta (scfv) prek krvno-možganske pregrade
CA2825064C (en) 2011-02-04 2022-08-30 Genentech, Inc. Fc variants and methods for their production
US10689447B2 (en) 2011-02-04 2020-06-23 Genentech, Inc. Fc variants and methods for their production
EA028804B1 (ru) 2011-03-25 2018-01-31 Гленмарк Фармасьютикалс С.А. Гетеродимерные иммуноглобулины
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
JP2015502397A (ja) 2011-12-23 2015-01-22 ファイザー・インク 部位特異的コンジュゲーションのための操作された抗体定常領域、ならびにそのための方法および使用
US9809641B2 (en) 2012-04-23 2017-11-07 Nrl Pharma, Inc. Lactoferrin fusion protein and method for preparation thereof
CN104520329A (zh) 2012-08-29 2015-04-15 霍夫曼-拉罗奇有限公司 血脑屏障穿梭体
EA032681B1 (ru) 2012-11-27 2019-07-31 Аджоу Юниверсити Индастри-Академик Кооперейшн Фаундейшн ГЕТЕРОДИМЕР Fc ИММУНОГЛОБУЛИНА, СОДЕРЖАЩИЙ ВАРИАНТ ДОМЕНА CH3 ДЛЯ ОБРАЗОВАНИЯ АНТИТЕЛА ИЛИ ГИБРИДНОГО БЕЛКА С ГЕТЕРОМЕРНЫМ Fc С ВЫСОКОЙ ЭФФЕКТИВНОСТЬЮ, СПОСОБ ДЛЯ ЕГО ПОЛУЧЕНИЯ И ИСПОЛЬЗОВАНИЯ
JP2016501881A (ja) 2012-12-04 2016-01-21 アッヴィ・インコーポレイテッド 血液脳関門（ｂｂｂ）を透過する二重特異性結合タンパク質
US20140348754A1 (en) 2013-05-14 2014-11-27 California Institute Of Technology Method of Delivering Therapeutics and Imaging Agents to the Brain by Nanoparticles that Cross the Blood Brain Barrier
EP2999716A2 (en) 2013-05-20 2016-03-30 F. Hoffmann-La Roche AG Anti-transferrin receptor antibodies and methods of use
US10465006B2 (en) 2013-07-05 2019-11-05 Genmab A/S Humanized or chimeric CD3 antibodies
EA202092386A1 (ru) 2013-07-31 2021-04-30 Эмджен Инк. Конструкции на основе фактора дифференцировки и роста 15 (gdf15)
WO2015024931A1 (en) 2013-08-19 2015-02-26 Moghimi Seyed Moien Peptidic nanodelivery composition targeting two receptors
CA2938577A1 (en) 2014-02-04 2015-08-13 New York University Progranulin (pgrn) and its derivatives for diagnosis and treatment of lysosomal storage diseases
CN105273087A (zh) * 2014-07-14 2016-01-27 复旦大学 NGF-Fc融合蛋白及其制备方法
AU2015346045B2 (en) 2014-11-14 2021-08-26 Ossianix, Inc. Variable new antigen receptors (VNARs) directed against transferrin receptor (TfR) and their use
US10508151B2 (en) 2014-11-19 2019-12-17 Genentech, Inc. Anti-transferrin receptor antibodies and methods of use
US11008403B2 (en) 2014-11-19 2021-05-18 Genentech, Inc. Anti-transferrin receptor / anti-BACE1 multispecific antibodies and methods of use
PL3221357T3 (pl) 2014-11-20 2020-11-02 F. Hoffmann-La Roche Ag Wspólne łańcuchy lekkie i sposoby zastosowania
DK3313879T3 (da) 2015-06-24 2022-03-14 Hoffmann La Roche Anti-transferrinreceptor-antistoffer med tilpasset affinitet
EA039366B1 (ru) 2015-06-24 2022-01-19 Джей Си Ар ФАРМАСЬЮТИКАЛЗ КО., ЛТД. Антитело к рецептору трансферрина человека, проникающее через гематоэнцефалический барьер
EP3313890A1 (en) 2015-06-24 2018-05-02 H. Hoffnabb-La Roche Ag Trispecific antibodies specific for her2 and a blood brain barrier receptor and methods of use
US11390656B2 (en) 2015-08-04 2022-07-19 New York University Progranulin (PGRN) fragments and derivatives for treatment or alleviation of lysosomal storage diseases
AU2016323440B2 (en) 2015-09-15 2023-07-13 Amgen Inc. Tetravalent bispecific and tetraspecific antigen binding proteins and uses thereof
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
WO2018013775A2 (en) 2016-07-14 2018-01-18 Emory University Granulin compositions and uses related thereto
IL276191B2 (en) 2016-12-26 2024-02-01 Japan Chem Res A new anti-human transferrin receptor antibody capable of penetrating the blood-brain barrier
EP3583123A1 (en) 2017-02-17 2019-12-25 Denali Therapeutics Inc. Anti-tau antibodies and methods of use thereof
AU2018221731C1 (en) 2017-02-17 2021-11-18 Denali Therapeutics Inc. Engineered transferrin receptor binding polypeptides
US10457717B2 (en) 2017-02-17 2019-10-29 Denali Therapeutics Inc. Engineered polypeptides
CN111148757A (zh) 2017-08-10 2020-05-12 戴纳立制药公司 工程改造的转铁蛋白受体结合多肽
MX2020002918A (es) 2017-10-02 2020-07-22 Denali Therapeutics Inc Proteinas de fusion que comprenden enzimas de terapia de reemplazo de enzimas.
WO2019094608A1 (en) 2017-11-08 2019-05-16 Denali Therapeutics Inc. Anti-bace1 antibodies and methods of use thereof
JP2021510162A (ja) 2018-01-10 2021-04-15 デナリ セラピューティクス インコーポレイテッドＤｅｎａｌｉ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． トランスフェリン受容体結合ポリペプチド及びその使用
KR102204521B1 (ko) 2018-04-17 2021-01-20 한국생명공학연구원 Ｐｒｏｇｒａｎｕｌｉｎ 단백질을 포함하는 간질환의 예방 또는 치료용 조성물
MX2020012518A (es) 2018-06-18 2021-02-16 Denali Therapeutics Inc Proteinas de fusion que comprenden progranulina.
MX2021001711A (es) 2018-08-16 2021-05-27 Denali Therapeutics Inc Proteínas biespecíficas modificadas.
AU2019326545A1 (en) 2018-08-22 2021-03-11 Denali Therapeutics Inc. Anti-HER2 polypeptides and methods of use thereof
JP2022513579A (ja) 2018-10-16 2022-02-09 デナリ セラピューティクス インコーポレイテッド プログラニュリン関連障害を処置及びモニタリングするための方法
CA3121927A1 (en) 2018-12-10 2020-06-18 Denali Therapeutics Inc. Lysosomal storage disorder biomarkers and methods of use thereof
CA3134538A1 (en) 2019-04-03 2020-10-08 Denali Therapeutics Inc. Formulations of protein molecules comprising iduronate 2-sulfatase
CN114981297A (zh) 2019-12-23 2022-08-30 戴纳立制药公司 颗粒蛋白前体变体
KR20220131246A (ko) 2020-01-13 2022-09-27 데날리 테라퓨틱스 인크. 항-trem2 항체 및 이의 사용 방법
EP4100419A1 (en) 2020-02-07 2022-12-14 Denali Therapeutics Inc. Methods for the treatment of hunter syndrome
CN116420078A (zh) 2020-10-14 2023-07-11 戴纳立制药公司 用于治疗和监测额颞痴呆的方法
IL302029A (en) 2020-10-14 2023-06-01 Denali Therapeutics Inc Fusion proteins containing sulfoglucosamine sulfohydrolase enzymes and methods thereof

Also Published As

Publication number Publication date
CN114981297A (zh) 2022-08-30
AU2020411480A1 (en) 2022-06-30
AU2020411480B2 (en) 2023-12-21
PE20230036A1 (es) 2023-01-10
CO2022008648A2 (es) 2022-06-30
US20220213155A1 (en) 2022-07-07
BR112022012230A2 (pt) 2022-08-30
US11643446B2 (en) 2023-05-09
KR20220130678A (ko) 2022-09-27
EP4081536A1 (en) 2022-11-02
JP2023507846A (ja) 2023-02-27
US20220220172A1 (en) 2022-07-14
CA3165846A1 (en) 2021-07-01
US20210188925A1 (en) 2021-06-24
US20230265137A1 (en) 2023-08-24
IL293994A (en) 2022-08-01

Similar Documents

Publication Publication Date Title
PH12020552189A1 (en) Fusion proteins comprising progranulin
MX2022007486A (es) Variantes de progranulina.
PH12018502361A1 (en) Gdf15 fusion proteins and uses thereof
MX2021000083A (es) Moleculas que activan selectivamente celulas t reguladoras para el tratamiento de enfermedades autoinmunes.
MX2019002867A (es) Metodos de tratamiento de trastornos inmunologicos usando proteinas de union a pd-1.
MY180831A (en) Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use
MX2020007628A (es) Composiciones y metodos de uso.
PH12020500054A1 (en) Novel therapeutic enzyme fusion protein and use thereof
MX2020006635A (es) Proteína de fusión enzimática terapéutica que tiene una nueva estructura y uso de la misma.
PH12019502869A1 (en) Agents, uses and methods for treatment
MX2022005866A (es) Anticuerpos biparatopicos frente a cd73.
EA201990593A1 (ru) Непрерывный способ для снижения гетерогенности терапевтического белка
AU2017259966A1 (en) TrkB agonist antibodies for treating neurodegenerative disorders
ZA202105101B (en) Peptides for treatment and prevention of diabetes and associated disorders
WO2018125799A3 (en) Metalloenzyme inhibitor compounds
ECSP22049014A (es) Variantes de progranulina
MX2021008081A (es) Tratamiento de la enfermedad de sjogren con proteinas de fusion de nucleasa.
EA202190062A1 (ru) Слитые белки, содержащие програнулин
MX2022008953A (es) Factores de transcripcion de proteina de dedos de zinc para reprimir la expresion de tau.
MX2022003192A (es) Proteinas de fusion nkg2d y sus usos.
MX2021013909A (es) Expresión de proteínas de unión a antígenos en el sistema nervioso.
AR115565A1 (es) Proteínas de fusión que comprenden progranulina
MX2022002774A (es) Método de captura y purificación de productos biológicos.
MX2023005063A (es) Proteinas de fusion sap fc y metodos de uso.
MX2023006297A (es) Moduladores de progranulina y metodos de uso de los mismos.